BioCentury | Aug 28, 2020
Emerging Company Profile

Concarlo: targeting proliferation and resistance in one go

Concarlo is developing targeted therapies for metastatic breast cancer that take aim at both CDK4/6-driven cell proliferation and CDK2-driven drug resistance in one go.  The company spun out of SUNY...
BioCentury | Jul 25, 2020
Translation in Brief

New class of cytosine base editors; plus new U.K. vaccine manufacturing facilities, scalable surrogate assay for COVID-19; combating antibiotic resistance and

New base editors widen template-free editing options A Massachusetts General Hospital team co-led by Beam Therapeutics Inc. (NASDAQ:BEAM) co-founder Keith Joung, and a Chinese Academy of Sciences team have separately developed a new class of...
BioCentury | Jul 16, 2020
Emerging Company Profile

Fountain Therapeutics: an AI-based platform to reverse cellular aging

Fountain is using an unbiased data-driven approach to identify compounds that reverse the biological process of aging, and in contrast to the traditional disease hypothesis-driven approach, the company is agnostic to indication. “Eighty percent of...
BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

While the late-stage programs for hearing loss are designed to protect cells in the inner ear, or help them recover from trauma, a growing number of early-stage therapies is aiming for a more dramatic outcome...
BioCentury | Aug 14, 2019
Distillery Therapeutics

RASGRF2-MEK inhibition for cocaine addiction

DISEASE CATEGORY: Neurology INDICATION: Addiction Blocking phosphorylation of MAPK1 and MAPK3 in the nucleus accumbens region of the brain by inhibiting RASGRF2-MEK signaling could treat cocaine addiction. In a mouse model of the addiction, the...
BioCentury | Jan 8, 2019
Distillery Therapeutics


INDICATION: Anxiety Mouse studies suggest depleting senescent cells could help treat obesity-induced anxiety. In a transgenic mouse model of obesity expressing the senescence marker human CDKN2A, a tool compound that depletes CDKN2A-positive cells decreased anxiety-like...
BioCentury | Sep 26, 2018
Distillery Therapeutics


INDICATION: Neurology Mouse models suggest clearing senescent cells could help treat tau-mediated neurodegenerative diseases. In a mouse model of tauopathy expressing mutant human tau in neurons, systemic expression of a fusion human transgene based on...
BioCentury | Sep 21, 2018
Tools & Techniques

Precision for pancreatic cancer

Real-time sequencing and organoid-based screens in pancreatic cancer could place new targets and biomarkers in the hands of drug developers looking for ways to side-step KRAS, a gene mutated in 90% of patients. Because KRAS...
BioCentury | Sep 19, 2018
Preclinical News

Mayo Clinic team implicates senescent cells in neurodegenerative diseases

Clearing out senescent brain cells could prevent tau-mediated neurodegeneration and cognitive loss, although it's still too early to determine whether the approach can halt or reverse disease progression, according to a Nature letter from Mayo...
BioCentury | Jan 31, 2018
Distillery Therapeutics


INDICATION: Parkinson's disease (PD) Patient samples and mouse studies suggest promoting clearance of CDKN2A-positive senescent cells could help treat PD. In postmortem substantia nigra tissue samples from patients, levels of the cellular senescence cell marker...
Items per page:
1 - 10 of 145